GSK Gobbles Up Sirtris For $720 Million, But Still Prefers Alliances To Big Buys
Executive Summary
GlaxoSmithKline's $720 million acquisition of the Cambridge, Mass.-based biotech Sirtris reflects an exception to, not the rule of, the U.K. drug manufacturer's deal-making strategy, according to company executives
You may also be interested in...
Epizyme Emerges From Stealth Mode
Tiny start-up aims to be a dominant player in the unfolding field of epigenetics.
Advice From A Biotech Winner: Sirtris’ Westphal Gives Upbeat Counsel To Industry
At the MassBio Investors Forum, Sirtris CEO talks about the importance of a “charged up” staff and the fun of working with parent company GSK to capture the biotech spirit.
Obesity-Focused Zafgen Raises Zaftig Series B
Three years after its launch, Zafgen emerges from stealth mode with a new CEO and another $14 million in funding.